National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019

This Determination rests on a small number of interlocking concepts that determine its operation.

• Commonwealth price: The Determination is concerned with how the Commonwealth price for a pharmaceutical benefit is ascertained for the purpose of making a payment to the supplier. Section 7(1) frames its role as providing "for the manner of ascertaining the Commonwealth price" for supplies by approved medical practitioners for payments under paragraph 98C(1)(a) of the Act. The instrument explicitly ties that calculation to the price rules in the pharmacist Determination (s 7(2)).

• Approved supplier categories: The instrument operates in relation to two categories of supplier defined by the National Health Act 1953, being "approved medical practitioner" and "approved pharmacist" (definitions in s 6 citing subsection 84(1) of the Act). The Determination treats those two supplier categories both as potential payees, and aligns pricing across them through the PB66 linkage.

• Conditions on payment: Part 3 sets the Determination’s enforcement mechanism as conditions on Commonwealth payment. Section 8 states that the Part sets out the conditions subject to which the Commonwealth will make payments in respect of supplies by approved pharmacists and approved medical practitioners. Two discrete conditions are expressed: brand specificity (s 9), and pack‑size completeness for listed drugs specified in Schedule 4 (s 10).

• External determinations and cross‑instrument reliance: The Determination refers to other legal instruments and statutory provisions for content and effect. It is made under s 98C(1) of the Act (s 3). It draws on the meaning of terms supplied by the Act, including "approved medical practitioner", "approved pharmacist", "brand", "listed drug", "pharmaceutical benefit" (s 6). It references the Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020 (PB 66 of 2020) as the source of pricing rules for medical practitioner supplies (s 7(2)). It also relies on determinations made under subsection 85(6) of the Act as the trigger for brand specificity (s 9).

• Standard formula preparation concept: Schedule 1 introduces the concept of an extemporaneously‑prepared pharmaceutical benefit being a "standard formula preparation" for pricing purposes, unless it varies from the described item by addition, omission, dose variation or combination (Schedule 1). The Schedule then lists forms, their standard formula preparation names, and a "pharmaceutical reference standard".

The Determination thus establishes a framework of delegated pricing and payment conditions that leverages the pharmacist pricing Determination, delegates brand selection to s 85(6) determinations under the Act, and specifies a defined list of extemporaneous preparations treated as standard formula preparations for price calculation unless they are altered.

This Determination affects a specific set of actors identified by the Act and the instrument.

• Approved medical practitioners and approved pharmacists: These are the direct financial stakeholders. Section 7 concerns the Commonwealth price for pharmaceutical benefits supplied by approved medical practitioners and explicitly aligns those prices with the pharmacist Determination (s 7(2)). Part 3 states that the Commonwealth will make payments in respect of supplies by approved pharmacists and approved medical practitioners only where the conditions in this Part are met (s 8). Thus both categories face operational and payment consequences.

• Patients and prescribers indirectly: Patients who receive prescriptions and prescribers who choose brands or specific pack sizes will be affected indirectly by the Determination’s payment conditions. Section 9 conditions Commonwealth payment on supply of a brand if a subsection 85(6) determination is in force. Section 10 conditions payment on supply of a complete pack for listed drugs in Schedule 4, even if a prescription requests a lesser quantity. Those conditions create an interface between prescribing practice, dispensing behaviour and Commonwealth payment outcomes.

• Commonwealth and its administrators: The Commonwealth, through the administrative machinery that implements payments for pharmaceutical benefits, is the paying party. The instrument sets payment rules and conditions of payment (s 8), which the responsible agency must implement operationally. The Determination was made under subsection 98C(1) of the Act (s 3), which is the statutory authority for the Commonwealth to make such determinations.

• Suppliers of extemporaneous preparations: Schedule 1 identifies extemporaneously prepared pharmaceutical benefits treated as standard formula preparations for pricing. Pharmacists or practitioners who prepare extemporaneous items listed in Schedule 1 should expect those items to be priced according to the schedule when the preparation conforms to the described formulation. If a preparation varies, it falls outside the standard formula preparation treatment (Schedule 1).

• Manufacturers and brand holders: Where a subsection 85(6) determination specifies a brand, that brand must be supplied for Commonwealth payment to be made (s 9). That mechanism concentrates payment eligibility on the specified brand, and therefore affects market demand for particular branded products identified by s 85(6) determinations.

• Entities connected to pack labelling and supply chains: Section 10 requires that, for listed drugs in Schedule 4 items, payments are made only if the quantity supplied equals the pack size described in column 2 of the item. That condition may affect inventory, dispensing stock management and repackaging choices by dispensers.

By setting payment outcomes on those concrete conditions, the Determination adjusts financial incentives for these actors. Approved practitioners and pharmacists who do not supply the specified brand or supply a lesser quantity than a required pack for Schedule 4 items risk not receiving Commonwealth payment for that supply (s 9, s 10). The instrument therefore affects choices about which brand to dispense, whether to break packs, and how to prepare extemporaneous items.

The Determination creates a limited set of duties (as conditions for payment) and preserves certain rights implicit in the statutory framework.

Key duties, expressed as conditions to Commonwealth payment

• Duty to calculate Commonwealth price as prescribed for medical practitioner supplies: Where an approved medical practitioner supplies a pharmaceutical benefit, the Commonwealth price for payment purposes must be ascertained in the manner set out for approved pharmacists in PB 66 of 2020. That is, approved medical practitioners do not have a separate pricing regime; the pricing rules for pharmacists govern the Commonwealth price for medical practitioner supplies (s 7(2)). Practitioners must therefore conform to the pricing methodology in PB 66 when claiming payment.

• Duty to supply the specified brand where a subsection 85(6) determination is in force: If a determination under subsection 85(6) of the National Health Act 1953 is in force that specifies a brand for a pharmaceutical item consisting of a drug or medicinal preparation, the Commonwealth will make payments only if that specified brand is supplied (s 9). This is an explicit condition on which brand of a product will attract Commonwealth payment.

• Duty to supply certain listed drugs only in the complete pack size described in Schedule 4 to receive payment: For listed drugs appearing in Schedule 4 in the specified form, the Commonwealth will pay only where the quantity supplied equals the quantity contained in the unit size described in column 2 for that Schedule 4 item, even if the prescription requests a lesser quantity (s 10). This imposes a duty on suppliers to match the pack size described in the Schedule to receive payment.

• Duty to observe the standard formula preparation rules: For extemporaneously prepared pharmaceutical benefits described in Schedule 1, those are treated as standard formula preparations for the purposes of working out the Commonwealth price, unless the benefit varies by addition, omission, dose variation, or combination of items (Schedule 1). Practitioners and pharmacists making extemporaneous preparations ought to ensure the preparation conforms to the Schedule 1 description if they expect the standard formula treatment to apply.

Rights and implied entitlements

• Right to payment where conditions are met: The Determination specifies conditions under which the Commonwealth will make payments. When an approved pharmacist or medical practitioner supplies pharmaceutical benefits in accordance with the Determination (including satisfying brand and pack requirements and applying the pricing rules from PB66 for medical practitioners), they are entitled to the Commonwealth payment as calculated. The instrument does not spell out procedural payment entitlement mechanics; rather it sets conditional eligibility.

• Right to rely on statutory definitions and other determinations: The Determination cross‑references and relies on statutory definitions supplied by the National Health Act 1953 and pricing rules in PB 66 of 2020. A supplier’s rights and duties are therefore shaped by those external instruments and statutory definitions (s 6; s 7(2)).

Operational implications of duties

• Recordkeeping and compliance: To establish entitlement to payment, suppliers will need to document that supplies conform to the brand requirements where an s 85(6) determination applies and that Schedule 4 pack sizes have been fully supplied where applicable. For extemporaneous preparations, suppliers must record that the preparation matches a Schedule 1 standard formula to support the pricing applied.

• Dependency on other instruments: The duty to use PB 66 pricing methods for medical practitioners and the duty to follow s 85(6) determinations means suppliers must monitor changes to those instruments. Section 7(2) explicitly makes PB 66 relevant to medical practitioner pricing, so changes to PB 66 will flow through to the price ascribed to medical practitioner supplies.

The Determination therefore places targeted, payment‑condition duties on suppliers and creates an expectation of payment when those duties are met, with clear cross‑dependencies on other statutory instruments.

The Determination itself does not create criminal offences or monetary penalties. Its enforcement mechanism operates through conditions for Commonwealth payment and administrative control over payment eligibility.

How enforcement is expressed in the instrument

• Conditions on payment as the enforcement mechanism: Part 3 expressly sets out "the conditions subject to which payments will be made by the Commonwealth" in respect of supplies by approved pharmacists and approved medical practitioners (s 8). Sections 9 and 10 articulate specific conditions. Non‑compliance with these conditions is therefore enforced by withholding Commonwealth payments for the supply in question. The Determination does not, within its text, prescribe fines, suspensions, administrative penalties, or prosecution for contravention.

• No specified penalty clauses within the instrument: The Determination does not include provisions that impose civil fines or criminal penalties for supplying a non‑specified brand where a subsection 85(6) determination applies, nor for supplying less than the complete pack size for Schedule 4 items. It restricts the circumstances under which the Commonwealth will make payment (s 9, s 10). Any penal consequences would need to derive from other provisions of the Act or other instruments, which are not set out in the Determination.

Administrative enforcement pathways

• Payment refusal and reconciliation: Practically, the primary administrative enforcement tool available to the Commonwealth under this Determination is to refuse to make payment to a supplier for a supply that does not meet the Determination’s conditions. The administering agency will need to check whether the supplied brand matches any s 85(6) determination and whether supplied quantities for Schedule 4 listed drugs correspond to the described pack sizes before authorising payment.

• Reliance on determinations under other provisions: Section 9 references determinations made under subsection 85(6) of the Act as the basis for constraining payment to a specified brand. Those determinations themselves may carry procedures or consequences beyond payment refusal, but those are not contained in the text of this Determination. The instrument therefore relies on the existence and effect of other determinations or statutory provisions for the shape of enforcement.

Potential enforcement and compliance friction points signalled by the instrument

• Practical effect is financial rather than punitive: Because the Determination sets eligibility for payment, the Commonwealth’s principal leverage is financial. Suppliers who supply non‑compliant brands or pack sizes may receive no Commonwealth payment for that supply, which is an economic sanction. The Determination does not set out additional sanctions in this text.

• Administrative discretion and its implications: The Determination requires the administering authority to determine whether a supply meets the criteria for payment. That requires factual assessments about brand conformity and pack sizes and application of the PB66 pricing methodology to medical practitioner supplies. The instrument therefore creates scope for administrative decision‑making about payment that will determine enforcement outcomes.

• Absence of internal dispute procedure in this text: The Determination does not set out dispute resolution, objection or review procedures for payment refusals. Any such mechanisms would need to be provided by the Act or general administrative law processes, neither of which are specified within this instrument.

In short, enforcement under the Determination is effected by conditioning Commonwealth payments; the instrument does not itself specify separate statutory penalties in its text. The administering agency’s operational decisions about payment eligibility are therefore the principal means by which compliance is enforced.

The Determination is explicitly interdependent with the National Health Act 1953 and with another Commonwealth price Determination. Its text signals layered legal interaction rather than standalone coverage.

Primary statutory source and delegated authority

• Made under s 98C(1) of the National Health Act 1953: The instrument states its authority is subsection 98C(1) of the National Health Act 1953 (s 3). That provision authorises the Commonwealth to make determinations about the Commonwealth price and conditions for payments for pharmaceutical benefits, and this Determination is an exercise of that delegated power.

References to statutory definitions

• Reliance on National Health Act definitions: Section 6 of the Determination adopts definitions from the National Health Act 1953. It ties key terms to the Act: "approved medical practitioner", "approved pharmacist", "brand", "listed drug", "pharmaceutical benefit" and "pharmaceutical item" are defined by reference to subsection 84(1) and section 84AB of the Act (s 6). That means the Determination’s substantive reach depends on the Act’s definitions. Interpretation of those terms will thus involve reading the Determination alongside the Act’s definitions and any applicable statutory interpretation principles in the Act.

Interaction with other determinations

• Imports pricing rules from PB 66 of 2020 for medical practitioner supplies: Section 7(2) directs that the Commonwealth price for a pharmaceutical benefit supplied by an approved medical practitioner is to be ascertained in the same manner as the price would have been worked out under the Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020 (PB 66 of 2020) if the supply had been by an approved pharmacist. The Determination therefore requires concurrent reading with PB 66, making the pharmacist pricing Determination an operational part of the legal framework for medical practitioner supplies.

• Relies on determinations under subsection 85(6) of the Act: Section 9 conditions Commonwealth payment on supplying a brand where a s 85(6) determination is in force specifying a brand for a pharmaceutical item. The s 85(6) determinations are therefore binding on payment decisions under this Determination. The content and legal effect of s 85(6) determinations are controlled by the Act’s provisions implementing subsection 85(6), not by this Determination itself.

Schedules and cross references

• Schedules interact with pricing and pack rules: The Determination states that Schedules 1, 2, 3 and 5 list pharmaceutical benefits and ingredients for which particular pricing rules apply (s 5; s 7(3)). Schedule 4 lists pharmaceutical benefits that must be supplied in complete packs for payment (s 5; s 10). These Schedules therefore allocate specific items to particular pricing or payment conditions and link back to the pricing rules of PB 66.

Consequences for legal interpretation and administration

• Necessity to read in context: Because the Determination imports pricing rules from PB 66 and depends on Act definitions and s 85(6) determinations, legal interpretation of its operation requires consulting those materials. The Determination does not stand alone; its full effect depends on other instruments and the Act.

• Change propagation risk: Changes to PB 66, to s 85(6) determinations or to the Act’s definitions can alter the practical effect of this Determination, because s 7(2) and s 9 import content from those other instruments. The Determination therefore functions as a node in a network of rules where modifications in one instrument can propagate to payment and pricing outcomes for medical practitioner supplies.

• Administrative overlap: The administering agency must manage cross‑instrument compliance, ensuring that pricing is calculated in accordance with PB 66 where relevant, that brand determinations under s 85(6) are enforced for payment purposes, and that Schedule 4 pack requirements are applied. This creates administrative dependencies across instruments and statutory powers.

In summary, this Determination is designed to be read and applied together with the National Health Act 1953 and the Commonwealth price Determination for pharmacists (PB 66 of 2020), and with any subsection 85(6) determinations that specify brands. Legal and administrative effects will therefore be shaped by those instruments as much as by this Determination’s text.

The instrument itself provides minimal direct information about prior amendments. The text identifies the instrument and its reference citation and situates it within the statutory power under which it is made.

Instrument identity and authorising provision

• Instrument name and citation: The Determination gives its name and citation at section 1: "This instrument is the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019" and "may also be cited as PB 114 of 2019" (s 1).

• Statutory authority: It is made under subsection 98C(1) of the National Health Act 1953 (s 3).

Internal cross references showing inter‑instrument reliance

• Reference to the pharmacist Determination PB 66 of 2020: Section 7(2) makes the Commonwealth price for supplies by approved medical practitioners contingent on the manner of calculation set out in the Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020 (PB 66 of 2020). That reference demonstrates that the Determination is designed to operate in concert with other determinations which may be made or updated subsequently to PB 114 of 2019.

What the instrument itself records about amendments

• The text includes no express amending provisions within the provided excerpt. There are no schedules of amendments in the text given. The Determination does not list dates of commencement or subsequent amendment entries within the fragments supplied.

Implication for amendment tracing

• To determine amendment history in full one must consult the official legislative instrument register, the Federal Register of Legislation, or the National Health Act 1953 amendment records. The Determination identifies itself as PB 114 of 2019 and points to PB 66 of 2020 as the relevant pricing Determination for medical practitioner supplies. Therefore, any subsequent changes to PB 66 or to s 85(6) determinations, or the Act itself, will impact the operation of PB 114; those changes will appear in the amendment history of the referenced instruments rather than necessarily within PB 114’s text.

• The Determination’s reliance on PB 66 of 2020 suggests that its practical operation may have been intended to be read in parallel with later instruments. The presence of a 2020 Determination cross‑referenced in a 2019 instrument indicates intertemporal linkage. Tracking amendment history for the regime therefore requires following both PB 114 and PB 66 and the Act.

Members of the public seeking authoritative amendment records should look to the instrument’s formal publication entry on the Federal Register of Legislation and to the consolidated versions of the National Health Act 1953 and the pharmacist pricing Determination. The Determination’s text as provided does not itself list amendments, reprints or commencement dates beyond the name and making provision.

The text of the Determination does not refer to any litigation, judicial consideration or decisions about its interpretation. It contains no schedule of case law or pointers to judicial enforcement. The instrument therefore does not record litigation history within its own content.

What the absence of litigation references means for practitioners and payees

• No cases cited in the instrument: The Determination does not name any cases, nor does it indicate prior dispute resolutions that interpret its terms. That means there is no jurisprudence provided within this instrument to clarify contested points such as the interpretation of the Schedule 1 standard formula exceptions, the precise circumstances in which a subsection 85(6) brand specification applies for payment, or the operation of the pack‑size requirement in Schedule 4.

• Dispute incubation through payment decisions: Because the Determination regulates eligibility for Commonwealth payment and does not establish criminal offences or express civil penalties within its text, disputes are most likely to arise where the administering agency refuses payment on the basis that a supply did not meet s 9 or s 10 conditions, or where there is disagreement about whether a given extemporaneous preparation falls within Schedule 1’s standard formula definition. Such disputes, if litigated, would appear in other fora and would need to be located in the broader administrative law and health law case law, which is not included here.

• Need to consult the Act and other instruments for adjudicative pathways: The Determination itself does not set out review or appeal mechanisms. Any litigation or judicial review would therefore have to rely upon the remedies available under the National Health Act 1953 or under general administrative law. The instrument does not provide internal procedures for payment review or appeal; it is silent on litigation processes.

Practical steps when facing an adverse payment decision

• Administrative review and records: A supplier who is declined payment under the Determination will need to rely on the Act and the administering agency’s procedures to seek reconsideration. Because the instrument conditions payment on detailed factual criteria (brand, pack size, adherence to Schedule 1 formulae), contemporaneous records showing compliance will be essential in any dispute.

• Monitoring case law updates: Practitioners and payees should monitor administrative decisions and court judgments that arise from disputes about payment refusals under the Act and readings of this Determination. Because this instrument is not accompanied by a litigation history section, locating relevant adjudications will require checking administrative tribunals and courts for disputes involving payments under the National Health Act 1953, and for cases that reference this Determination or PB 66.

In short, the Determination contains no litigation history in its text. Disputes arising from its application will be resolved through administrative and judicial processes outside the instrument, and any jurisprudential guidance will need to be sourced from case law and tribunal decisions concerning the Act and associated determinations.

This Determination contains several provisions that create discrete operational traps for suppliers if they are not anticipated. The "gotchas" below are drawn directly from the instrument’s mechanisms and cross‑dependencies that change payment outcomes.

1. Commonwealth payment depends on compliance with external determinations

• Price calculation for medical practitioners is not autonomous: Section 7(2) directs that the Commonwealth price for a supply by an approved medical practitioner is to be ascertained in the same manner as if PB 66 of 2020 governed a pharmacist supply. This means changes in PB 66 will affect medical practitioner pricing automatically. If administrators or suppliers assume a different pricing method for medical practitioners, payments may be adjusted or refused.

2. Brand specification via s 85(6) determinations removes discretion to substitute

• If a subsection 85(6) determination specifies a brand, the Commonwealth will pay only for supply of that brand (s 9). Suppliers who substitute a therapeutically equivalent brand without checking for an s 85(6) specification risk not being paid. This will be a concrete operational issue where stock constraints or commercial supply changes make substitution tempting.

3. Pack‑size requirement may cause non‑payment even when partial supplies are clinically appropriate

• Section 10 requires that, for Schedule 4 listed drugs in a described form, payments will be made only if the quantity supplied equals the pack size in column 2, even if the prescription asks for a lesser quantity. A pharmacist or medical practitioner who dispenses a smaller quantity to meet clinical needs or patient affordability will not receive Commonwealth payment if the item is a Schedule 4 listed drug subject to the pack requirement. That creates a tension between prescribing/dispensing flexibility and payment eligibility.

4. Extemporaneous preparations are standard only when they exactly match the schedule description

• Schedule 1 treats listed extemporaneous preparations as standard formula preparations unless there is an addition, omission, dose variation or combination of benefits across items (Schedule 1). An apparently minor variation to an extemporaneous recipe can therefore have an outsized effect on pricing treatment and payment calculation. Suppliers who make small formulation changes may inadvertently move the item outside the standard formula pricing regime.

5. Administrative reliance produces operational complexity

• The Determination requires administrators to check multiple sources: the Act’s s 85(6) determinations for brand specifications, the PB 66 pharmacist pricing Determination for pricing methodology, and the Schedules for pack and formula requirements. Failure to synchronise these sources in payment processing may lead to incorrect payment decisions or unexpected recoupments.

6. No internal penalty schedule but financial exposure remains

• The Determination lacks express penalty clauses but conditions payment on precise compliance. Non‑compliant supply can therefore result in non‑payment, creating immediate financial exposure for the supplier. Suppliers used to expecting payment for dispensed medicines should not assume that supply equates to payment without confirming compliance with the Determination’s conditions.

7. Timing and cross‑instrument changes can create retroactivity risks

• Because PB 114 of 2019 imports PB 66 of 2020 for pricing medical practitioner supplies, suppliers must be alert to the timing of changes in PB 66. If PB 66 is updated, the price method applied to medical practitioner supplies may change without a separate amendment to PB 114, possibly affecting claims made under the Determination. Suppliers should track effective dates of referenced determinations.

8. Unclear recordkeeping expectations in the Determination

• The instrument does not specify what documentation is required to show compliance with s 9 or s 10. Because payment eligibility depends on factual determinations about what brand was supplied and the quantity supplied relative to Schedule 4 pack sizes, suppliers should maintain contemporaneous dispensing records and stock records to support any future payment claim or dispute.

9. Potential misalignment between clinical practice and payment rules

• The pack‑size rule in s 10 can produce a perverse result where prescribers and patients want a smaller amount for clinical or economic reasons, but the Commonwealth will not pay unless the full pack is supplied. Suppliers who follow clinical judgement and supply smaller quantities may find that the Commonwealth refuses payment, leaving them to absorb the cost or seek patient payment.

These "gotchas" are not regulatory interpretations beyond the text. They are concrete consequences of the Determination’s provisions that suppliers, prescribers and administrators must anticipate and manage through policy, process and recordkeeping.

Compliance with this Determination is a practical and administrative process focused on meeting the payment conditions and applying the prescribed pricing methodology. The following steps are grounded in the instrument’s text and identify necessary actions for approved medical practitioners, approved pharmacists and administering agencies.

1. Confirm legal status and definitions

• Ensure the supplier is an "approved medical practitioner" or "approved pharmacist" as defined in subsection 84(1) of the National Health Act 1953, since the Determination operates only in relation to those categories (see s 6 definitions referencing subsection 84(1) of the Act). Suppliers should verify their approval status and retain evidence of approval because payment eligibility flows from that status.

2. For medical practitioners, apply pharmacist pricing rules

• When an approved medical practitioner supplies a pharmaceutical benefit, calculate the Commonwealth price in the manner set out in the Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020 (PB 66 of 2020), as if the supply had been made by an approved pharmacist (s 7(2)). This requires maintaining a current copy of PB 66 and applying its pricing methodology to medical practitioner supplies for Commonwealth payment claims.

3. Monitor and comply with s 85(6) brand determinations

• Before dispensing a brand, check whether a determination under subsection 85(6) of the Act is in force for that pharmaceutical item. If such a determination specifies a brand, supply that specified brand to be eligible for Commonwealth payment (s 9). Maintain a process to check the register of s 85(6) determinations and a record of the brand dispensed for each payment claim.

4. For Schedule 4 listed drugs, supply the complete pack size stated

• If the pharmaceutical benefit is a listed drug appearing in Schedule 4 in the form described in columns 1 and 2, ensure the supplied quantity equals the pack size described in column 2 to be paid by the Commonwealth, even if the prescription requests a lesser quantity (s 10). Adjust inventory and dispensing practices to accommodate full‑pack dispensing where Schedule 4 items are implicated, and record the pack size supplied in dispensing records.

5. For extemporaneous preparations, adhere to Schedule 1 formulations

• When preparing extemporaneous pharmaceutical items, verify whether the preparation matches a Schedule 1 standard formula preparation exactly. If it matches and there are no additions, omissions, dose variations or combinations across items, treat it as a standard formula preparation for pricing (Schedule 1). If the preparation deviates, note that it will not be treated as a standard formula preparation under the Schedule. Keep precise formulation records, batch sheets and prescriptions that justify the formula used.

6. Maintain robust recordkeeping and evidence trails

• For each supply claimed for Commonwealth payment, retain records that demonstrate compliance with the Determination’s conditions: proof of supplier status, the brand supplied and its authorising s 85(6) determination if applicable, the pack size supplied for Schedule 4 drugs, and formulation details for extemporaneous preparations. Robust records will be essential if payment is questioned or recouped.

7. Coordinate with administering agency processes

• Ensure that billing and claims systems are configured to apply PB 66 pricing rules for medical practitioner supplies and to flag s 85(6) brand requirements and Schedule 4 pack conditions. Implement internal controls to prevent submission of claims that do not meet the Determination’s conditions.

8. Monitor changes to referenced instruments

• Because the Determination imports PB 66 pricing methodology for medical practitioner supplies and depends on s 85(6) determinations, maintain active monitoring of updates to PB 66, newly made or varied s 85(6) determinations, and amendments to the National Health Act 1953 definitions relevant to "approved practitioner", "brand", "listed drug" and "pharmaceutical item" (s 6). Update internal compliance guidance promptly when referenced instruments change.

9. Policy and patient communication

• Where pack‑size requirements (s 10) obligate full‑pack supply to receive payment, develop counselling and billing processes to inform patients of the payment consequences if they request smaller quantities. Consider documenting patient consent where a differing supply model is necessary and manage financial arrangements to address shortfalls if Commonwealth payment is unavailable.

10. Audit readiness

• Prepare for administrative audits by ensuring that claims include the detailed information necessary to demonstrate compliance with the Determination’s conditions. This includes the formula used for extemporaneous items, brand identity aligned to s 85(6) determinations, and factual evidence of pack sizes supplied for Schedule 4 items.

Following these steps aligns operational behaviour with the Determination’s text. The central compliance touchpoints are: applying PB 66 pricing methodology to medical practitioner supplies (s 7(2)), supplying s 85(6) specified brands where those determinations exist (s 9), and supplying complete pack sizes for Schedule 4 listed drugs (s 10). Rigorous recordkeeping and monitoring of referenced instruments will reduce the risk of payment refusal under the Determination.